Afuco™ Anti-GD3 Ganglioside ADCC Therapeutic Antibody (Ecromeximab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to GD3 ganglioside. Ecromeximab is a chimeric monoclonal antibody being developed for the treatment of malignant melanoma.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-TAB-131 |
| Pricing | Inquiry |
| Host | Chimeric |
| Target | GD3 Ganglioside |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Applications | FC, IP, ELISA, Neut, FuncS, IF |
| Storage | Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |